153 related articles for article (PubMed ID: 34017084)
1. Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database.
Jensen KH; Vogelius I; Moser CE; Andersen E; Eriksen JG; Johansen J; Farhadi M; Andersen M; Overgaard J; Friborg J
Br J Cancer; 2021 Aug; 125(3):458-464. PubMed ID: 34017084
[TBL] [Abstract][Full Text] [Related]
2. Early Mortality after Radical Radiotherapy in Head and Neck Cancer - A Nationwide Analysis from the Danish Head and Neck Cancer Group (DAHANCA) Database.
Jensen KH; Vogelius I; Kristensen CA; Andersen E; Overgaard J; Eriksen JG; Primdahl H; Johansen J; Farhadi M; Andersen M; Friborg J
Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):57-63. PubMed ID: 32698963
[TBL] [Abstract][Full Text] [Related]
3. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
[TBL] [Abstract][Full Text] [Related]
5. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
6. Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma.
Jensen KH; Vogelius IR; Bernsdorf M; Gothelf A; Kristensen CA; Maare C; Andersen E; Specht L; Friborg J
Radiother Oncol; 2022 Jun; 171():1-6. PubMed ID: 35395275
[TBL] [Abstract][Full Text] [Related]
7. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
8. The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC.
Tasoulas J; Lenze NR; Farquhar D; P Schrank T; Shen C; Shazib MA; Singer B; Patel S; Grilley Olson JE; Hayes DN; Gulley ML; Chera BS; Hackman T; Olshan AF; Weiss J; Sheth S
Cancer Med; 2021 May; 10(10):3231-3239. PubMed ID: 33934525
[TBL] [Abstract][Full Text] [Related]
9. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
10. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.
Amini A; Jones BL; McDermott JD; Serracino HS; Jimeno A; Raben D; Ghosh D; Bowles DW; Karam SD
Cancer; 2016 May; 122(10):1533-43. PubMed ID: 26969811
[TBL] [Abstract][Full Text] [Related]
11. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
12. Early (90-day) mortality after radical radiotherapy for head and neck squamous cell carcinoma: A population-based analysis.
Hamilton SN; Tran E; Berthelet E; Wu J; Olson R
Head Neck; 2018 Nov; 40(11):2432-2440. PubMed ID: 30295975
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of curative (chemo)radiotherapy for patients with non-p16 positive head and neck squamous cell carcinoma who are borderline for curative treatment.
Xing D; Tiong A; Bressel M; Rischin D; Tran P; Corry J
J Med Imaging Radiat Oncol; 2020 Apr; 64(2):271-278. PubMed ID: 32037733
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
[TBL] [Abstract][Full Text] [Related]
15. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database.
Bøje CR; Dalton SO; Primdahl H; Kristensen CA; Andersen E; Johansen J; Andersen LJ; Overgaard J
Radiother Oncol; 2014 Jan; 110(1):91-7. PubMed ID: 24412015
[TBL] [Abstract][Full Text] [Related]
17. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.
Patimarattananan T; Nongnuch A; Pattaranutaporn P; Unwanatham N; Jiarpinitnun C; Ngamphaiboon N
Support Care Cancer; 2021 Feb; 29(2):877-887. PubMed ID: 32524284
[TBL] [Abstract][Full Text] [Related]
18. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
Chang CL; Yuan KS; Wu SY
Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
[TBL] [Abstract][Full Text] [Related]
19. Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation.
Zumsteg ZS; Luu M; Kim S; Tighiouart M; Mita A; Scher KS; Lu DJ; Shiao SL; Mallen-St Clair J; Ho AS
Ann Oncol; 2019 Jan; 30(1):76-84. PubMed ID: 30395159
[TBL] [Abstract][Full Text] [Related]
20. Role of concomitant chemoradiation in locally advanced head and neck cancers.
Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
